Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis

Abstract

Objective Perennial allergic rhinitis (PAR) affects children at a young age. Current guidelines recommend intranasal corticosteroids as the first-line treatment in patients with moderate-to-severe or persistent disease or in those who have congestion. In this study, the long-term safety and efficacy of mometasone furoate nasal spray (MFNS) were assessed in children with PAR. Methods In this multicenter, active-controlled, evaluator-blind, 12-month study, 255 children aged 6–11 years with a ≥1-year history of PAR were randomized to receive once-daily MFNS 100 μg ( n = 166) or the active comparator beclomethasone dipropionate (BDP) 168 μg ( n = 85). Changes from baseline in overall PAR symptoms and response to treatment were rated at each visit. Cosyntropin stimulation testing, as well as tonometry and slit lamp procedures, were performed. Safety variables were assessed. Results A total of 137 subjects in the MFNS group and 68 in the BDP group completed treatment. The mean reductions in physician- and subject-rated overall condition of PAR at week 52 were −42.1% and −39.7%, respectively, for MFNS, compared with −44.0% and −39.0%, respectively, for BDP. A total of 94% and 100% of MFNS and BDP subjects, respectively, reported adverse events (AEs), which were mostly mild or moderate. The most frequently reported treatment-related AEs in both groups were epistaxis, headache, and pharyngitis. Response to cosyntropin was normal and no posterior subcapsular cataracts were observed in either group. Although no significant changes in intraocular pressure were observed with MFNS, one subject receiving BDP demonstrated this effect. Conclusions Treatment with MFNS 100 μg once daily for 1 year was well tolerated in children 6–11 years old, with negligible systemic exposure and no evidence of suppression of the hypothalamic–pituitary–adrenal axis or ocular changes.